EXPERIMENTAL AND BASIC RESEARCH STUDIES
Characteristics of equine mesenchymal stem cells derived from amnion and bone marrow: In vitro proliferative and multilineage potential assessment
Article first published online: 26 MAR 2013
© 2013 EVJ Ltd
Equine Veterinary Journal
Volume 45, Issue 6, pages 737–744, November 2013
How to Cite
Lange-Consiglio, A., Corradetti, B., Meucci, A., Perego, R., Bizzaro, D. and Cremonesi, F. (2013), Characteristics of equine mesenchymal stem cells derived from amnion and bone marrow: In vitro proliferative and multilineage potential assessment. Equine Veterinary Journal, 45: 737–744. doi: 10.1111/evj.12052
- Issue published online: 14 OCT 2013
- Article first published online: 26 MAR 2013
- Accepted manuscript online: 17 JAN 2013 05:03AM EST
- Manuscript Accepted: 30 DEC 2012
- Manuscript Received: 29 JUL 2012
- amniotic mesenchymal cells;
- bone marrow mesenchymal cells;
Reasons for performing study
This is the first study comparing stemness features of equine mesenchymal progenitor cells derived from amniotic membrane and bone marrow.
To investigate an alternative and noninvasive stromal cell source for equine tissue engineering.
In vitro experimental study of the characteristics of equine mesenchymal progenitor cells derived from amnion and bone marrow.
Cells isolated from amniotic membrane and bone marrow were analysed for proliferation (growth curve, doubling time, colony forming unit). Immunocytochemical detection of pluripotency markers and gene expression of stromal cell markers were also performed and these cells were studied for multilineage plasticity.
Amniotic stromal cells (AMSCs) and bone marrow mesenchymal cells (BM-MSCs) both exhibited mature stromal cell-specific gene expression and immunocytochemical properties, but showed substantial differences in their proliferative and differentiation potential. The mean doubling time for AMSCs was significantly lower (P<0.05) than that observed for BM-MSCs (1.17 ± 0.15 vs. 3.27 ± 0.19 days, respectively). Compared to AMSCs, BM-MSCs also demonstrated a significantly (P<0.05) lower clonogenic capability (one fibroblast-like colony forming unit from a mean of 590.15 cells seeded for BM-MSCs vs. 242.73 cells seeded for AMSCs). BM-MSCs did not differentiate into glial cells, and the osteogenic differentiation process was longer than for AMSCs.
Conclusions and potential relevance
The amniotic membrane could be a valuable source of MSCs to be used both for allogenic and/or autologous therapies. The noninvasive nature and low cost of collection, the rapid proliferation along with a greater differentiation potential and the ‘off the shelf’ preparation potential could make AMCs useful for cell therapy.